Cardiology

P-gp/CYP3A4 inhibitor use ups bleeding, mortality risks in NOAC-treated AF patients

8 hours ago

Bleeding and mortality risks are elevated in atrial fibrillation (AF) patients treated with nonvitamin K antagonist oral anticoagulant (NOAC) who are also using P-glycoprotein (P-gp) and CYP3A4 inhibitors, reports a study, noting the need for close monitoring of these individuals.

MACE, stroke, death common after acute coronary syndrome in people with bipolar disorder

Yesterday

In people with bipolar disorder, major adverse cardiovascular events (MACE) are common occurrences after acute coronary syndrome (ACS), a new study has found. Similarly, the risks of all-cause mortality and stroke are also increased post-ACS.

Dabigatran continues to be safe, useful in NVAF patients during idarucizumab era

2 days ago

Even after the dabigatran-specific reversal agent idarucizumab has been made available, dabigatran continues to be safe and well-tolerated for stroke and systemic embolism prevention in patients with nonvalvular atrial fibrillation (NVAF), reports a recent Japan study.

Cardiovascular events complicate condition of sepsis patients

Stephen Padilla, 3 days ago

Cardiovascular events (CVEs) pose more problems in half of critically ill patients with sepsis, with nearly four in five developing CVEs within the first week of hospitalization, leading to longer intensive care unit (ICU) and hospital length of stay (LOS), a Singapore study has shown.

SGLT2is reduce serious hyperkalaemia risk in T2D, CKD patients

Audrey Abella, 3 days ago

Sodium-glucose cotransporter 2 inhibitors (SGLT2is) consistently reduced the risk of serious hyperkalaemia (serum potassium [K+] ≥6.0 mmol/L) without increasing the risk of hypokalaemia (serum K+ ≤3.5 mmol/L) in individuals with type 2 diabetes (T2D) at high cardiovascular (CV) risk, or in those with chronic kidney disease (CKD), a meta-analysis has shown.

Ramipril shows favourable effects in hypertensive kids on maintenance haemodialysis

5 days ago

In hypertensive children undergoing maintenance haemodialysis, ramipril helps improve biomarkers of endothelial dysfunction and inflammation in addition to its blood pressure (BP)-lowering benefits, a study has found.

$Empagliflozin: A new dawn for heart failure treatment across the ejection fraction spectrum$

Empagliflozin: A new dawn for heart failure treatment across the ejection fraction spectrum

06 Jun 2022

Initially approved to improve glycaemic control and reduce cardiovascular death in adults with type 2 diabetes (T2D), the SGLT-2* inhibitor empagliflozin reduced hospitalization for heart failure (HFH) or cardiovascular death and delayed renal function decline when added to recommended therapy in patients with heart failure and reduced ejection fraction (HFrEF) in the EMPEROR-Reduced** trial. The EMPEROR-Preserved** trial has now shown that the benefits of empagliflozin extend to patients with heart failure and preserved ejection fraction (HFpEF).

Early and consistent: Breakthrough results in HFpEF similar to HFrEF

14 Jan 2022

HFpEF represents a significant unmet need in CV medicine due to its prevalence, poor prognosis, and the absence of clinically proven therapeutic options. The EMPEROR-Preserved trial demonstrated the continuous clinical benefits in cardiorenal outcomes of empagliflozin in adults with HFpEF, which were consistent with the observations in adults with HFmrEF/ HFpEF in the EMPEROR-reduced trial. The combined results of the EMPEROR trials establish empagliflozin’s efficacy in heart failure regardless of ejection fraction – and if approved, empagliflozin would become the first and only clinically proven therapy to improve outcomes for the full spectrum of the disease. Therefore, empagliflozin offers a new hope for people living with heart failure.

EMPEROR-Preserved: The first successful trial to improve outcomes in HFpEF

18 Nov 2021

Heart failure with preserved ejection fraction (HFpEF) represents a significant unmet medical need. The EMPEROR-Preserved trial aimed to assess the impact of empagliflozin on cardiovascular outcomes in patients with HFpEF. On 27 August 2021, during the hotline session of the 2021 ESC Virtual Congress, the main results of the EMPEROR-Preserved trial were presented by Professor Stefan Anker, principal investigator of the study, and heart failure specialist at Charité Berlin, Germany.

NOACs in nonvalvular atrial fibrillation with multimorbidity: Where does apixaban stand?

02 Nov 2021

Atrial fibrillation (AF) is the most common cardiac arrhythmia encountered in clinical practice, affecting millions of people globally. Stroke is one of its devastating complications, with the risk steeply increasing with advancing age. Additionally, AF is associated with more than a tripling of the risk of systemic embolic (SE) events. [J Am Heart Assoc 2020;9:e016724]

Trimetazidine new formulation redefining angina control in daily practice

12 Mar 2021

Chronic coronary syndrome (CCS) remains a leading cause of death and disability worldwide. The dual goals of CCS management is to prevent future cardiac events, such as myocardial infarction and death, and to reduce ischaemia and relieve angina symptoms, says Prof Peter Yan, consultant cardiologist and medical director, Peter Yan Cardiology Clinic, Gleneagles Medical Centre, Singapore, during a Servier-sponsored virtual symposium.

Paclitaxel-coated devices in femoropopliteal artery revascularization: Mortality risk fears unfounded?

Roshini Claire Anthony, 10 Jun 2022

Among patients undergoing femoropopliteal artery revascularization, mortality risk was not affected regardless of whether they were treated with drug-coated devices (DCDs) or non–drug-coated devices (NDCDs), according to updated results of the SAFE-PAD* study presented at SCAI 2022.

Clopidogrel monotherapy trumps aspirin monotherapy in reducing CV events post-PCI

Roshini Claire Anthony, 03 Jun 2022

One year after undergoing percutaneous coronary intervention (PCI), high-risk patients on clopidogrel monotherapy have a reduced risk of multiple cardiovascular (CV) outcomes compared with those on aspirin monotherapy, according to a study presented at SCAI 2022.

IVL maintains superiority over PTA at 1 year for peripheral artery calcification

Audrey Abella, 03 Jun 2022

In the Disrupt PAD III trial, superior primary patency (PP) was achieved at 1 year with intravascular lithotripsy (IVL) plus a drug-coated balloon (DCB) compared with percutaneous transluminal angioplasty (PTA) + DCB, confirming the consistent safety and efficacy of IVL to facilitate a durable approach for individuals with heavily calcified femoropopliteal arteries largely without stent requirement.

Harmony TPV continues to show safety, efficacy for recipients at 1 year

Audrey Abella, 02 Jun 2022

In an expanded analysis presented at SCAI 2022, recipients of the Harmony transcatheter pulmonary valve (TPV) continued to demonstrate favourable clinical and haemodynamic outcomes, confirming previous results and showing continued device success across studies and valve types at 1 year and beyond.

Post-TAVR SLT does not differ with edoxaban or DAPT

Post-TAVR SLT risk does not differ with edoxaban or DAPT

Roshini Claire Anthony, 16 May 2022

The risk of subclinical valve leaflet thrombosis (SLT) following transcatheter aortic valve replacement (TAVR) did not differ regardless of whether patients received edoxaban or dual antiplatelet therapy (DAPT) post-surgery, according to results of the ADAPT-TAVR* trial.

New HF guideline: Quad therapy, HFmrEF, and more

Elvira Manzano, 04 May 2022

Hot on the heels of ACC.22 ground-breaking reports, the ACC/AHA/HFSA* released the 2022 heart failure (HF) guideline, with special emphasis on quad therapy for patients with reduced ejection fraction.

Which DOAC is safest to use in AF patients on dronedarone therapy?

Stephen Padilla, 02 May 2022

Among patients on concomitant treatment with direct oral anticoagulants (DOACs) and dronedarone, no difference is seen in survival free from the composite endpoint (ie, clinically relevant bleeding, thromboembolic event, and all-cause death) and from clinically relevant bleeding between groups of coadministration, according to a study.